Identification of key genes for diabetic kidney disease using biological informatics methods

Ma,Fuzhe; Sun,Tao; Wu,Meiyan; Wang,Wanning; Xu,Zhonggao

doi:10.3892/mmr.2017.7666

Identification of key genes for diabetic kidney disease using biological informatics methods

Authors:
- Fuzhe Ma
- Tao Sun
- Meiyan Wu
- Wanning Wang
- Zhonggao Xu
View Affiliations

Affiliations: Department of Nephrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7666
Pages: 7931-7938
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic kidney disease (DKD) is a common complication of diabetes, which is characterized by albuminuria, impaired glomerular filtration rate or a combination of the two. The aim of the present study was to identify the potential key genes involved in DKD progression and to subsequently investigate the underlying mechanism involved in DKD development. The array data of GSE30528 including 9 DKD and 13 control samples was downloaded from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) in DKD glomerular and tubular kidney biopsy tissues were compared with normal tissues, and were analyzed using the limma package. Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for DEGs using the GO Function software in Bioconductor. The protein‑protein interaction (PPI) network was then constructed using Cytoscape software. A total of 426 genes (115 up‑ and 311 downregulated) were differentially expressed between the DKD and normal tissue samples. The PPI network was constructed with 184 nodes and 335 edges. Vascular endothelial growth factor A (VEGFA), α‑actinin‑4 (ACTN4), proto‑oncogene, Src family tyrosine kinase (FYN), collagen, type 1, α2 (COL1A2) and insulin‑like growth factor 1 (IGF1) were hub proteins. Major histocompatibility complex, class II, DP α1 (HLA‑DPA1) was the common gene enriched in the rheumatoid arthritis and systemic lupus erythematosus pathways, and the immune response was a GO term enriched in module A. VEGFA, ACTN4, FYN, COL1A2, IGF1 and HLA‑DPA1 may be potential key genes associated with the progression of DKD, and immune mechanisms may serve a part in DKD development.

View Figures

View References

1	Association AD: Standards of medical care in diabetes-2010. Diabetes care. 33 Suppl:S11–S61. 2010. View Article : Google Scholar :
2	Levin A and Rocco M: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 49(2 Suppl 2): S12–S154. 2007.
3	Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM and Susztak K: Transcriptome analysis of human diabetic kidney disease. Diabetes. 60:2354–2369. 2011. View Article : Google Scholar :
4	Susztak K, Raff AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–233. 2006. View Article : Google Scholar
5	Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthöfer H, Zaoui P, Pinel N, Cordonnier DJ and Gilbert RE: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: Effects of angiotensin converting enzyme inhibition. Diabetologia. 45:1572–1576. 2002. View Article : Google Scholar
6	Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G and Camussi G: Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 52:1023–1030. 2003. View Article : Google Scholar
7	Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Paul LC and Bruijn JA: Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol. 14:2063–2071. 2003. View Article : Google Scholar
8	Turk T, Leeuwis JW, Gray J, Torti SV, Lyons KM, Nguyen TQ and Goldschmeding R: BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem. 57:623–631. 2009. View Article : Google Scholar :
9	Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, et al: Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 18:1765–1776. 2007. View Article : Google Scholar
10	Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA and Hugo CP: Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 69:1654–1661. 2006. View Article : Google Scholar
11	Nath KA: The tubulointerstitium in progressive renal disease. Kidney Int. 54:992–994. 1998. View Article : Google Scholar
12	Gilbert RE and Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 56:1627–1637. 1999. View Article : Google Scholar
13	Strippoli GF, Craig M, Deeks JJ, Schena FP and Craig JC: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ. 329:8282004. View Article : Google Scholar :
14	Hansen TK, Forsblom C, Saraheimo M, Thorn L, Wadén J, Høyem P, Østergaard J, Flyvbjerg A and Groop PH; FinnDiane Study Group, : Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 53:1517–1524. 2010. View Article : Google Scholar : PubMed/NCBI
15	Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
16	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
17	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
18	Altermann E and Klaenhammer TR: PathwayVoyager: Pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. BMC Genomics. 6:602005. View Article : Google Scholar : PubMed/NCBI
19	Wang J, Zhou X, Zhu J, Gu Y, Zhao W, Zou J and Guo Z: GO-function: Deriving biologically relevant functions from statistically significant functions. Brief Bioinform. 13:216–227. 2012. View Article : Google Scholar : PubMed/NCBI
20	Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al: The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ichinose K, Kawasaki E and Eguchi K: Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol. 27:554–564. 2007. View Article : Google Scholar : PubMed/NCBI
23	Galkina E and Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol. 17:368–377. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC and Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int. 65:116–128. 2004. View Article : Google Scholar : PubMed/NCBI
25	Tuttle KR: Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 16:1537–1538. 2005. View Article : Google Scholar : PubMed/NCBI
26	Mora C and Navarro JF: Inflammation and diabetic nephropathy. Curr Diab Rep. 6:463–468. 2006. View Article : Google Scholar : PubMed/NCBI
27	Johnston SL, Virgo PF and Unsworth DJ: Type 1 diabetes mellitus masking primary antibody deficiency. J Clin Pathol. 53:236–237. 2000. View Article : Google Scholar : PubMed/NCBI
28	Prevoo ML, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB and Van Riel PL: Modified disease activity scores that include twenty-eight-joint counts, development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38:44–48. 1995. View Article : Google Scholar : PubMed/NCBI
29	Feng PH: Systemic lupus erythematosus: the face of Asia. Ann N Y Acad Sci. 1108:114–120. 2007. View Article : Google Scholar : PubMed/NCBI
30	Varney MD, Valdes AM, Carlson JA, Noble JA, Tait BD, Bonella P, Lavant E, Fear AL, Louey A, Moonsamy P, et al: HLA DPA1, DPB1 alleles and haplotypes contribute to the risk associated with type 1 diabetes: Analysis of the type 1 diabetes genetics consortium families. Diabetes. 59:2055–2062. 2010. View Article : Google Scholar : PubMed/NCBI
31	Santin I, Castellanos-Rubio A, Aransay AM, Gutierrez G, Gaztambide S, Rica I, Vicario JL, Noble JA, Castaño L and Bilbao JR: Exploring the diabetogenicity of the HLA-B18-DR3 CEH: Independent association with T1D genetic risk close to HLA-DOA. Genes Immun. 10:596–600. 2009. View Article : Google Scholar : PubMed/NCBI
32	Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1029–1039. 1995.PubMed/NCBI
33	Schrijvers BF, Flyvbjerg A and De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65:2003–2017. 2004. View Article : Google Scholar : PubMed/NCBI
34	Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E and Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 43:636–650. 2004. View Article : Google Scholar : PubMed/NCBI
35	Bortoloso E, Del Prete D, Vestra M Dalla, Gambaro G, Saller A, Antonucci F, Baggio B, Anglani F and Fioretto P: Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol. 150:799–807. 2004. View Article : Google Scholar : PubMed/NCBI
36	Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK and Won NH: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl. 77:S104–S112. 2000. View Article : Google Scholar : PubMed/NCBI
37	Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH and Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 111:707–716. 2003. View Article : Google Scholar : PubMed/NCBI
38	Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH and Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 19:442–455. 2003. View Article : Google Scholar : PubMed/NCBI
39	Nikolopoulos SN, Spengler BA, Kisselbach K, Evans AE, Biedler JL and Ross RA: The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. Oncogene. 19:380–386. 2000. View Article : Google Scholar : PubMed/NCBI
40	HA TS: High glucose and advanced glycosylated end-products affect the expression of alpha-actinin-4 in glomerular epithelial cells. Nephrology (Carlton). 11:435–441. 2006. View Article : Google Scholar : PubMed/NCBI
41	Jefferson JA, Shankland SJ and Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int. 74:22–36. 2008. View Article : Google Scholar : PubMed/NCBI
42	Resh MD: Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol. 30:1159–1162. 1998. View Article : Google Scholar : PubMed/NCBI
43	Taniguchi K, Xia L, Goldberg HJ, Lee KW, Shah A, Stavar L, Masson EA, Momen A, Shikatani EA, John R, et al: Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in Mice. Diabetes. 62:3874–3886. 2013. View Article : Google Scholar : PubMed/NCBI
44	van Nieuw Amerongen GP and van Hinsbergh VW: Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vascular pharmacol. 39:257–272. 2002. View Article : Google Scholar
45	Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ and Natarajan R: MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA. 104:pp. 3432–3437. 2007; View Article : Google Scholar : PubMed/NCBI
46	Kato M, Arce L and Natarajan R: MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol. 4:1255–1266. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ewens KG, George RA, Sharma K, Ziyadeh FN and Spielman RS: Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes. 54:3305–3318. 2005. View Article : Google Scholar : PubMed/NCBI
48	Schreiber B, Hughes M and Groggel G: Insulin-like growth factor-1 stimulates production of mesangial cell matrix components. Clin Nephrol. 43:368–374. 1995.PubMed/NCBI